Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Jacobi

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Annals of the Rheumatic Diseases|February 7, 2009
HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosusA M Jacobi, H Mei, B F Hoyer, et al.
Zeitschrift Fur Rheumatologie|May 17, 2017
[Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)]N Venhoff, F Proft, H Schulze-Koops, et al.
Lupus|November 11, 2011
Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus reportM Aringer, H Burkhardt, G R Burmester, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Annals of the Rheumatic Diseases|February 7, 2009
HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosusA M Jacobi, H Mei, B F Hoyer, et al.
Zeitschrift Fur Rheumatologie|May 17, 2017
[Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)]N Venhoff, F Proft, H Schulze-Koops, et al.
Lupus|November 11, 2011
Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus reportM Aringer, H Burkhardt, G R Burmester, et al.
Pageof 3